Apmonia Therapeutics
PrivateLast Round
Series A
Feb 3, 2026
Total Funding Raised
$17.4M
Company Overview
Apmonia Therapeutics is a biotechnology company that develops peptide-based immunotherapy strategies for the treatment of solid tumors by targeting the tumor microenvironment.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Medical AI
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Infrastructure
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Apmonia Therapeutics Comps
Public and private peers based on sector, stage, and business model.
| Company | Status | Est. Valuation | Rev Multiple |
|---|---|---|---|
| OpenAI | Private | $86.0B | ~40x |
| Cohere | Private | $5.0B | -- |
| Competitor 1 | Public | $XX.XB | XXx |
| Competitor 2 | Public | $XX.XB | XXx |
Apmonia Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Feb 3, 2026 | ||||
| Grant | Jul 16, 2024 | ||||
| Grant | Apr 23, 2024 | ||||
| VC Round | Feb 10, 2022 |
Key People
Founding team and executive leadership
Apmonia Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| France 2030 | Grant |
| European Innovation Council Fund | Grant |
| Angels Santé | Series A, VC Round |
| Finovam Gestion | Series A, VC Round |
| Capital Grand Est | Series A, VC Round |
| Business Angels Marne Ardennes | Seed |
| Capital Cell | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Feb 21, 2026
Grew 27% QoQ from 15 to 19 employees.
Apmonia Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Apmonia Therapeutics's valuation, stock price, and market status.